Interventional radiologists have opened the door to an encouraging potential future treatment for the nearly 200,000 women who are diagnosed with breast cancer in the United States each year: image-guided, multiprobe cryotherapy…
Globalepolicy.org is a free to access global medical news service for the consumer, professional and researcher.
Background: A treatment algorithm and screening examination have been developed to guide patient management and prospectively determine potential for highly active individuals to succeed with nonoperative care after anterior cruciate ligament rupture.
Objective: To prospectively characterize and classify the entire population of highly active individuals over a 10-year period and provide final outcomes for individuals who elected nonoperative care.
Methods: Inclusion criteria included presentation within 7 months of the index injury and an International Knee Documentation Committee level I or II activity level before injury. Concomitant injury, unresolved impairments, and a screening examination were used as criteria to guide management and classify individuals as noncopers (poor potential) or potential copers (good potential) for nonoperative care.
Results: A total of 832 highly active patients with subacute anterior cruciate ligament tears were seen over the 10-year period; 315 had concomitant injuries, 87 had unresolved impairments, and 85 did not participate in the classification algorithm. The remaining 345 patients (216 men, 129 women) participated in the screening examination a mean of 6 weeks after the index injury. There were 199 subjects classified as noncopers and 146 as potential copers. Sixty-three of 88 potential copers successfully returned to preinjury activities without surgery, with 25 of these patients not undergoing anterior cruciate ligament reconstruction at the time of follow-up.
Conclusion: The classification algorithm is an effective tool for prospectively identifying individuals early after anterior cruciate ligament injury who want to pursue nonoperative care or must delay surgical intervention and have good potential to do so.
NAVIGATION
|
17
Mar |
Encouraging Interventional Radiology Potential Treatment For Breast Cancer With CryotherapyCategory: Breast Cancer | Leave a Comment |
Interventional radiologists have opened the door to an encouraging potential future treatment for the nearly 200,000 women who are diagnosed with breast cancer in the United States each year: image-guided, multiprobe cryotherapy…
|
12
Mar |
Technology May Reduce Need For Repeat Cancer SurgeryCategory: Breast Cancer | Leave a Comment |
Every year more than 100,000 women in the United States undergo a lumpectomy, a conservative procedure to remove cancerous tumors while preserving the breast. The surgeon’s goal is to attain a tumor-free, or negative, surgical margin the first time they operate…
|
3
Mar |
TechniScan Launches 3-D Breast Ultrasound Clinical Study In Freiburg UniversityCategory: Breast Cancer | Leave a Comment |
TechniScan, Inc. (OTC Bulletin Board: TSNI) (”TechniScan” or the “Company”), a medical device company engaged in the development and commercialization of an automated 3-D breast ultrasound imaging system, announced that in collaboration with University Medical Center Freiburg in Germany, it has launched a clinical study to assess clinical utility of TechniScan’s Warm Bath Ultrasound…
|
19
Feb |
MU Researcher Developing A Sensor To Detect Diseases, Such As Breast Cancer, In Bodily FluidsCategory: Breast Cancer | Leave a Comment |
What if it were possible to go to the store and buy a kit to quickly and accurately diagnose cancer, similar to a pregnancy test? A University of Missouri researcher is developing a tiny sensor, known as an acoustic resonant sensor, that is smaller than a human hair and could test bodily fluids for a variety of diseases, including breast and prostate cancers…
|
12
Feb |
Reoperation Rate For Breast Cancer: Addition Of MRI To Conventional Assessment Has No Effect (COMICE Study)Category: Breast Cancer | Leave a Comment |
An article published in this week’s edition of The Lancet reports that addition of magnetic resonance imaging (MRI) scans to conventional triple assessment techniques for diagnosis of breast cancer has no effect on the reoperation rate…
|
10
Feb |
Agendia Receives New York State Laboratory Permit And Laboratory Accreditation By College Of American PathologistsCategory: Breast Cancer | Leave a Comment |
Agendia, a world leader in molecular cancer diagnostics, announced that it has received the Clinical Laboratory Permit from the New York State Department of Health. The New York State permit allows the company to receive commercial samples of MammaPrint, its FDA-cleared breast cancer recurrence test. With this latest permit, Agendia has now obtained all major U.S. clinical laboratory licenses…
|
1
Feb |
Important Advance In Imaging Of Cell DeathCategory: Breast Cancer | Leave a Comment |
For quite some time, the “Holy Grail” in medical imaging has been the development of an effective method to image cell death as a means to intervene early in diseases and rapidly determine the effectiveness of treatments…
|
25
Jan |
Future Treatment Choices Could Be Guided By Genes Linked To Breast Cancer Drug ResistanceCategory: Breast Cancer | Leave a Comment |
Researchers at Dana-Farber Cancer Institute have discovered a gene activity signature that predicts a high risk of cancer recurrence in certain breast tumors that have been treated with commonly used chemotherapy drugs…
|
18
Dec |
FDA Broadens Clearance For Agendia’s MammaPrint(R)Category: Breast Cancer | Leave a Comment |
Agendia, a world leader in molecular cancer diagnostics, announced that the US Food and Drug Administration (FDA) cleared its MammaPrint breast cancer recurrence test for all ages. MammaPrint is the only FDA-cleared breast cancer recurrence test available to patients and physicians…
|
18
Dec |
FDA Broadens Clearance For Agendia’s MammaPrint(R)Category: Breast Cancer | Leave a Comment |
Agendia, a world leader in molecular cancer diagnostics, announced that the US Food and Drug Administration (FDA) cleared its MammaPrint breast cancer recurrence test for all ages. MammaPrint is the only FDA-cleared breast cancer recurrence test available to patients and physicians…